Product Code: RP-ID-10094778 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10094778
Market Overview:
Atorvastatin API Market Segmentation by Distribution Channel (Online, and Offline); and by Application (Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Global Atorvastatin API Market Highlights Over 2022 - 2031
The global atorvastatin API market is estimated to grow at a CAGR of ~4% over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a notable revenue in 2021. The growth of the market can be attributed to the rise in the risk of high cholesterol, owing to which there has been an increase in kidney and heart issues. According to the World Health Organization, cardiovascular diseases are the top most reason for death globally, accounting for 17.9 million deaths each year. Furthermore, a rise in the percentage of the population with poor living habits has led to an increase in obesity cases. As per the World Obesity Organization, it is anticipated that 268 million school-age children and 2.7 billion adults will be obese by 2025. Moreover, there has been an increase in the population that is expected to drive the growth of the global atorvastatin API market.
GET A SAMPLE COPY OF THIS REPORT
The COVID-19 pandemic had a positive impact on the pharma industry. People who were already suffering from cardiovascular disease and chronic kidney disease got infected by the virus easily owing to their low immunity system. The demand for the medicines was greater as compared to the supply, considering the restrictive government measures. Therefore, the COVID-19 pandemic is anticipated to drive the growth of the global atorvastatin API market.
The global atorvastatin API market is segmented by application into dyslipidemia, hypercholesterolemia, hypertriglyceridemia, and others. Out of these, the hypercholesterolemia segment is anticipated to hold the largest share in the market over the forecast period. This can be attributed to the high prevalence of hypercholesterolemia among people. Moreover, the number of hypercholesterolemia cases globally will grow in the future, that is expected to contribute to the growth of the hypercholesterolemia segment.
Global Atorvastatin API Market Regional Synopsis
Regionally, the global atorvastatin API market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. On the strength of the presence of the huge amount of raw materials required for the production of atorvastatin, the market in the North America region is expected to hold the largest share by the end of 2031. The market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increase in the number of coronary heart disease cases and growth in the pharma industry. According to the National Library of Medicine, during the last 40 years, there has been a 4 times rise of coronary heart disease prevalence in India. Moreover, there has been an increase in the population that is expected to contribute to the growth of the atorvastatin API market in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global atorvastatin API market includes the following segments:
By Distribution Channel
-
Online
-
Offline
By Application
-
Dyslipidemia
-
Hypercholesterolemia
-
Hypertriglyceridemia
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Atorvastatin API Market
Growth Drivers
-
Increase in the heart and kidney issues
-
Rise in the deteriorating lifestyle habits of people
Challenges
-
Lack of inventory of raw materials
-
High cost for the procurement of raw materials
Key Companies Dominating the Global Atorvastatin API Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global atorvastatin API market that are included in our report are Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Centrient Pharmaceuticals, Cadila Pharmaceuticals., ZHEJIANG HISUN PHARMACEUTICAL Co., LTD., Sun Pharmaceutical Industries Ltd., Jubilant Pharmova Limited, Anuh Pharma Ltd., Morepen Laboratories Ltd., Ind- Swift Ltd., and others.
Latest Developments in the Global Atorvastatin API Market:
-
5 August 2020: Teva Pharmaceutical Industries Ltd., announced its partnership with Alvotech to commercialize five biosimilar candidates in United States. The purpose of the collaboration is to improve the lives of patients through developing quality medications.
-
3 February 2022: Dr Reddy’s Laboratories Ltd., announced the acquisition of Nimbus Health GmbH, a pharmaceutical wholesaler in Germany. The company wants to introduce cannabis-based medicines as a treatment option for patients.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Centrient Pharmaceuticals
- Cadila Pharmaceuticals.
- ZHEJIANG HISUN PHARMACEUTICAL Co.LTD.
- Sun Pharmaceutical Industries Ltd.
- Jubilant Pharmova Limited
- Anuh Pharma Ltd.
- Morepen Laboratories Ltd.
- Ind- Swift Ltd.
Related Reports
Proof of Quality & Reliability
